Articoli correlati a Effectiveness and Safety of Radium-223 Dichloride:...
Risultati della ricerca per Effectiveness and Safety of Radium-223 Dichloride:...
Foto dell'editore
Effectiveness and Safety of Radium-223 Dichloride
Editore:
Our Knowledge Publishing Okt 2023, 2023
ISBN 10: 6206581640
ISBN 13: 9786206581642
Nuovo
Taschenbuch
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
Valutazione del venditore 5 su 5 stelle
Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. 60 pp. Englisch. Codice articolo 9786206581642
Compra nuovo
EUR 45,90
Spedizione EUR 23,00
Spedito da Germania a U.S.A.
Spedito da Germania a U.S.A.
Quantità: 2 disponibili
Immagini fornite dal venditore
Effectiveness and Safety of Radium-223 Dichloride : Modifications in its indication
Print on DemandDa: AHA-BUCH GmbH, Einbeck, Germania
Valutazione del venditore 5 su 5 stelle
Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. Codice articolo 9786206581642
Compra nuovo
EUR 48,74
Spedizione EUR 35,00
Spedito da Germania a U.S.A.
Spedito da Germania a U.S.A.
Quantità: 1 disponibili
Immagini fornite dal venditore
Effectiveness and Safety of Radium-223 Dichloride
Da: moluna, Greven, Germania
Valutazione del venditore 5 su 5 stelle
Condizione: New. Codice articolo 1188787031
Compra nuovo
EUR 37,04
Spedizione EUR 48,99
Spedito da Germania a U.S.A.
Spedito da Germania a U.S.A.
Quantità: Più di 20 disponibili
Immagini fornite dal venditore
Effectiveness and Safety of Radium-223 Dichloride
Editore:
Our Knowledge Publishing Okt 2023, 2023
ISBN 10: 6206581640
ISBN 13: 9786206581642
Nuovo
Taschenbuch
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
Valutazione del venditore 5 su 5 stelle
Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 60 pp. Englisch. Codice articolo 9786206581642
Compra nuovo
EUR 45,90
Spedizione EUR 60,00
Spedito da Germania a U.S.A.
Spedito da Germania a U.S.A.
Quantità: 1 disponibili